PMID- 33133775
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2164-2591 (Print)
IS  - 2164-2591 (Electronic)
IS  - 2164-2591 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Oct
TI  - Validation of an Automated Quantification of Relative Ellipsoid Zone Reflectivity 
      on Spectral Domain-Optical Coherence Tomography Images.
PG  - 17
LID - 10.1167/tvst.9.11.17 [doi]
LID - 17
AB  - PURPOSE: Relative ellipsoid zone reflectivity (rEZR) represents a potential 
      biomarker of photoreceptor health on spectral-domain optical coherence tomography 
      (SD-OCT). Because manual quantification of rEZR is laborious and lacks of spatial 
      resolution, automated quantification of the rEZR would be beneficial. The purpose 
      of this study was to evaluate the reliability and reproducibility of an automated 
      rEZR quantification method. METHODS: The rEZR was acquired using a manual and an 
      automated approach in eyes with age-related macular degeneration (AMD) and 
      healthy controls. The rEZR obtained from both methods was compared and the 
      agreement between the methods and their reproducibility assessed. RESULTS: Forty 
      eyes of 40 participants with a mean (+/- standard deviation) age of 65.2 +/- 7.8 
      years were included. Both the manual and automated method showed that control 
      eyes exhibit a greater rEZR than AMD eyes (P < 0.001). Overall, the limits of 
      agreement between the manual and automated method were -7.5 to 7.3 arbitrary 
      units (AU) and 95% of the data points had a difference in the rEZR between the 
      methods of +/-8.2%. An expected perfect reproducibility was observed for the 
      automated method, whereas the manual method had a coefficient of repeatability of 
      6.3 arbitrary units. CONCLUSIONS: The automated quantification of rEZR method is 
      reliable and reproducible. Further studies of the rEZR as a novel biomarker for 
      AMD severity and progression are warranted. TRANSLATIONAL RELEVANCE: Automated 
      quantification of SD-OCT-based rEZR allows for its comprehensive and longitudinal 
      characterization evaluating its relevance as an in vivo biomarker of 
      photoreceptor function and its prognostic value for AMD progression.
CI  - Copyright 2020 The Authors.
FAU - Thiele, Sarah
AU  - Thiele S
AD  - Department of Ophthalmology, University of Bonn, Bonn, Germany.
AD  - GRADE Reading Center, University of Bonn, Bonn, Germany.
FAU - Isselmann, Ben
AU  - Isselmann B
AD  - Department of Ophthalmology, University of Bonn, Bonn, Germany.
FAU - Pfau, Maximilian
AU  - Pfau M
AD  - Department of Ophthalmology, University of Bonn, Bonn, Germany.
AD  - GRADE Reading Center, University of Bonn, Bonn, Germany.
AD  - Department of Biomedical Data Science, Stanford University, Stanford, California, 
      USA.
FAU - Holz, Frank G
AU  - Holz FG
AD  - Department of Ophthalmology, University of Bonn, Bonn, Germany.
AD  - GRADE Reading Center, University of Bonn, Bonn, Germany.
FAU - Schmitz-Valckenberg, Steffen
AU  - Schmitz-Valckenberg S
AD  - Department of Ophthalmology, University of Bonn, Bonn, Germany.
AD  - GRADE Reading Center, University of Bonn, Bonn, Germany.
FAU - Wu, Zhichao
AU  - Wu Z
AD  - Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East 
      Melbourne, Australia.
AD  - Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, 
      Australia.
FAU - Guymer, Robyn H
AU  - Guymer RH
AD  - Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East 
      Melbourne, Australia.
AD  - Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, 
      Australia.
FAU - Luu, Chi D
AU  - Luu CD
AD  - Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East 
      Melbourne, Australia.
AD  - Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201014
PL  - United States
TA  - Transl Vis Sci Technol
JT  - Translational vision science & technology
JID - 101595919
MH  - Aged
MH  - Humans
MH  - *Macular Degeneration/diagnostic imaging
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - *Tomography, Optical Coherence
PMC - PMC7581490
OTO - NOTNLM
OT  - biomarker
OT  - imaging
OT  - reflectivity
COIS- Disclosure: S. Thiele, Heidelberg Engineering (R, F); Optos (F), Zeiss (F), 
      CenterVue (F); Novartis (R); Bayer (R); B. Isselmann, None; M. Pfau, Heidelberg 
      Engineering (F); Optos (F), Zeiss (F), CenterVue (F); F.G. Holz, Acucela (C, F, 
      R), Allergan (F, R), Apellis (C, R), Bayer (C, F, R), Boehringer-Ingelheim (C), 
      Bioeq/Formycon (F, C), CenterVue (F), Ellex (R), Roche/Genentech (C, F, R), 
      Geuder (C), Grayburg Vision (C, R), Heidelberg Engineering (C, F, R), Kanghong 
      (C, F), LinBioscience (C, R), NightStarX (F), Novartis (C, F, R), Optos (F), 
      Pixium Vision (C, F, R), Oxurion (C, R), Stealth BioTherapeutics (C, R), Zeiss 
      (F, R); S. Schmitz-Valckenberg, Acucela/Kubota Vision (F), Novartis (C, F, R); 
      Allergan (C, F, R); Bayer (F, R); Bioeq/Formycon (F, C); Carl Zeiss MedicTec (F, 
      R); CenterVue (F); Galimedix (C), Genentech/Roche (F, R); Heidelberg Engineering 
      (F); Katairo (F), Optos (F), Oxurion (C), Roche/Genentech (F, C); Z. Wu, None; 
      R.H. Guymer, Novartis (S), Bayer (S), Roche Genentech (S), Appelis (S); C.D. Luu, 
      None
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
PMCR- 2020/10/14
CRDT- 2020/11/02 06:18
PHST- 2020/07/02 00:00 [received]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/11/02 06:18 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
PHST- 2020/10/14 00:00 [pmc-release]
AID - TVST-20-2818 [pii]
AID - 10.1167/tvst.9.11.17 [doi]
PST - epublish
SO  - Transl Vis Sci Technol. 2020 Oct 14;9(11):17. doi: 10.1167/tvst.9.11.17. 
      eCollection 2020 Oct.